Breaking News
March 23, 2018 - New computational method helps to identify tumor cell mutations with greater accuracy
March 23, 2018 - Wales participates in the 100,000 Genomes Project
March 23, 2018 - 24-Hr Paging Cuts ED Visits for Kids with Endocrine Issues
March 23, 2018 - The brain learns completely differently than we’ve assumed since the 20th century
March 23, 2018 - Less nutritious diet mainly contributes to Type 2 diabetes among U.S.-based South Asians
March 23, 2018 - Stony Brook Medicine expert provides tips for healthy diet to decrease cancer risk
March 23, 2018 - New findings could have revolutionary impact on quality of life of older people
March 23, 2018 - Restoring enzyme may help reverse effects of vascular aging, study shows
March 23, 2018 - Protein profiling reveals new prostate cancer mechanisms
March 23, 2018 - FDA Takes Aim at Flavored Tobacco
March 23, 2018 - SMART Strategy Lowers Asthma Exacerbation Risk
March 23, 2018 - Cold open water plunge provides instant pain relief
March 23, 2018 - Patients with vascular malformations have poor health-related quality of life
March 23, 2018 - New DOD grant to support testing of promising therapy for triple-negative breast cancer
March 23, 2018 - Novel vaccine technologies can help better prepare for future infectious disease threats
March 23, 2018 - OncoBreak: Colonoscopy TV; Coverage for Genomic Testing; Care for Caregivers
March 23, 2018 - For some surgeries, nerve blocks mean better outcomes, fewer opioids
March 23, 2018 - Maternal obesity and androgen excess induce sex-specific anxiety in offspring, study suggests
March 23, 2018 - The tale of Theranos and the mysterious fire alarm
March 23, 2018 - USC researchers create algorithm to optimize substance abuse intervention groups
March 23, 2018 - Impulsivity may be associated with greater weight loss during treatment in obese children
March 23, 2018 - CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
March 23, 2018 - Senate Panel Addresses Native Americans’ Opioid Troubles
March 23, 2018 - Brain connections in schizophrenia
March 23, 2018 - Mental health assessment in health checks can help detect psychologically vulnerable people
March 23, 2018 - New test for urothelial cancers offers less invasive, more accurate detection
March 23, 2018 - Groundbreaking 100,000 Genomes Project achieves important milestone to transform NHS care
March 23, 2018 - Mice getting a new lease of life with anti-aging pills
March 23, 2018 - Obesity kills taste buds and dulls taste sensation finds study
March 23, 2018 - Medical students get less formal education in radiation oncology, study finds
March 23, 2018 - Researchers find investigational compound to treat triple negative breast cancer after brain metastasis
March 23, 2018 - Researchers develop wearable system to monitor electrical activity in the stomach over 24 hours
March 23, 2018 - A Different Opioid Crisis | Medpage Today
March 23, 2018 - PTSD an ongoing fight for generation of Iraq War vets
March 23, 2018 - Researchers uncover specific gene region in hypertension
March 23, 2018 - Specific immune cells may help slow progression of ALS, research shows
March 23, 2018 - Biosense Webster launches new ‘Power to Heal’ campaign to alleviate AF burden
March 23, 2018 - FDA could curb or ban tobacco in menthol or fruit flavoured cigarettes soon
March 23, 2018 - Mom’s Pre-Pregnancy Waist Size Tied to Autism Risk
March 23, 2018 - AMD Treat-and-Extend Regimens OK: Ophthalmology Times
March 23, 2018 - Safe-sleep recommendations for infants have not reduced sudden deaths in newborns
March 23, 2018 - Survey finds inappropriate prescribing of antibiotics for hospitalized children
March 23, 2018 - Researchers propose alternative treatment to target lymphoma signaling at its root
March 22, 2018 - Compound found in beet extract could help slow progression of Alzheimer’s disease
March 22, 2018 - Lower temperatures can trigger the body’s ‘good’ fat formation at cellular level
March 22, 2018 - Sentinel lymph node biopsies could be safely avoided for some breast cancer patients
March 22, 2018 - Combined Preeclampsia Test Superior to U.K. Standards
March 22, 2018 - Exclusive breastfeeding in hospital associated with longer breastfeeding duration
March 22, 2018 - Researchers prove link between common childhood cancer and inflammation
March 22, 2018 - Targeting aberrantly active telomerase to treat therapy-resistant melanoma
March 22, 2018 - California’s tax on millionaires yields big benefits for people with mental illness, study finds
March 22, 2018 - Weight-loss surgery reduces risk for severe chronic kidney disease and kidney failure
March 22, 2018 - Study identifies two genes associated with extreme nausea and vomiting during pregnancy
March 22, 2018 - Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine
March 22, 2018 - ‘Bionic Pancreas’ OK for Very Young T1D Patients
March 22, 2018 - Parkinson’s gene initiates disease outside of the brain
March 22, 2018 - NMSU researchers publish findings on effective measures to remedy stress among adolescents
March 22, 2018 - Immunotherapy combination increases overall survival in people with kidney cancer, study shows
March 22, 2018 - Increased rate of accidental injuries associated with poorer hearing ability
March 22, 2018 - Gut microbiome may promote pancreatic cancer by inducing immune suppression
March 22, 2018 - New ocular inserts allow patient’s cornea to absorb more antibiotics
March 22, 2018 - FDA Alert: NeuroBlate Probe by Monteris Medical: Letter to Health Care Providers, Class I Recall
March 22, 2018 - Cessation of exercise can result in increased depressive symptoms
March 22, 2018 - Morning Break: Booze Study Brouhaha; Stem Cells for MS; Big Debt Problem
March 22, 2018 - New wearable tech from Western may hold big benefits for people with Parkinson’s
March 22, 2018 - Immune cells can repopulate in the retina after elimination, mice study shows
March 22, 2018 - States extend Medicaid for birth control, cutting costs — and future enrollment
March 22, 2018 - Research provides better understanding of how cancerous cells behave in low oxygen
March 22, 2018 - Menopausal hormone therapy taken soon after menopause may benefit the brain
March 22, 2018 - Booze Boosts Your Heart Rate
March 22, 2018 - Skeptical Cardiologist: Classifying Heart Failure
March 22, 2018 - Instead of nagging your spouse to lose weight, try going on a diet yourself
March 22, 2018 - Neem Biotech to share findings on cystic fibrosis biofilm disruption at ECFS Basic Science Conference
March 22, 2018 - Study uncovers new genetic cause of posterior polymorphous corneal dystrophy
March 22, 2018 - ENDO: Big Breakfast May Help in Diabetics
March 22, 2018 - I’m not overweight, so why do I need to eat healthy foods?
March 22, 2018 - UCLA-led study suggests unexpected reason for reduction in cardiovascular health disparities
March 22, 2018 - Study suggests detailed neuropsychological assessment for brief cardiac arrest survivors
March 22, 2018 - Anticoagulant drugs found safe to use in patients undergoing surgery for irregular heartbeat
March 22, 2018 - SP Industries appoints Brian Larkin as new President and CEO
Novel consortium aims to create new paradigm of cancer drug discovery

Novel consortium aims to create new paradigm of cancer drug discovery

image_pdfDownload PDFimage_print

Scientists from two U.S. national laboratories, industry and academia today launched an unprecedented effort to transform the way cancer drugs are discovered by creating an open and sharable platform that integrates high-performance computing, shared biological data from public and industry sources and emerging biotechnologies to dramatically accelerate the discovery of effective cancer therapies.

The goal of the consortium – Accelerating Therapeutics for Opportunities in Medicine (ATOM) – is to create a new paradigm of drug discovery that would reduce the time from an identified drug target to clinical candidate from the current approximately six years to just 12 months. ATOM aims to transform cancer drug discovery from a time-consuming, sequential and high-risk process into an approach that is rapid, integrated and with better patient outcomes — using supercomputers to pretest many molecules simultaneously for safety and efficacy.

The consortium comprises the Department of Energy’s Lawrence Livermore National Laboratory (LLNL), GSK, the National Cancer Institute’s Frederick National Laboratory for Cancer Research (FNLCR), and the University of California, San Francisco (UCSF). ATOM welcomes additional public and private partners who share the vision.

“The goals of ATOM are tightly aligned with those of the 21st Century Cures Act, which aims in part to enable a greater number of therapies to reach more patients more quickly,” said FNLCR Laboratory Director David Heimbrook. “Although initially focused on precision oncology – treatments targeted specifically to the characteristics of the individual patient’s cancer – the consortium’s discoveries could accelerate drug discovery against many diseases.”

ATOM will develop, test and validate a multidisciplinary approach to drug discovery in which modern science, technology and engineering, supercomputing simulations, data science and artificial intelligence are highly integrated into a single drug-discovery platform that can untimately be shared with the drug development community at large.

“As we have learned more about what modern supercomputers can do, we’ve gained confidence that this approach can make a big difference in creating medicines,” said John Baldoni, senior vice president, R&D at GSK. “We must do all that we can to reduce the time it takes to get medicines to patients. GSK is working to set a precedent with pharmaceutical companies by sharing data on failed compounds.”

GSK will initially contribute chemical and in vitro biological data for more than 2 million compounds from its historic and current screening collection, as well as preclinical and clinical information on 500 molecules that have failed in development but could help accelerate development of new compounds by providing knowledge about the underlying biology of candidate compounds and that of the human body. Combined with data on successful drugs, GSK’s offering represents a broad base of information for ATOM researchers. In addition, GSK will provide expertise in drug discovery and development, computational chemistry and biology.

The ATOM team will combine data provided by GSK with publicly available data, and that of future consortium members, to generate new dynamic models that can better predict how molecules will behave in the body compared to the current iterative and time-consuming practices. In this effort, LLNL will contribute its best-in-class supercomputers, including its next-generation system Sierra, as well as its expertise and innovative approaches to modeling and simulation, cognitive computing, machine learning and algorithm development. More broadly, by tackling the ambitious challenge of cancer therapies, ATOM will drive technologies vital to the core missions of the Department of Energy and National Nuclear Security Administration (NNSA).

“ATOM is a novel public-private partnership that draws on the lab’s unique capabilities to create a paradigm change in drug development,” said LLNL Director Bill Goldstein. “It will help to strengthen U.S. leadership in high-performance computing and, by speeding the discovery of therapeutics, contribute to biosecurity.”

For its part, FNLCR will contribute from its wealth of scientific expertise in precision oncology, computational chemistry and cancer biology, as well as support for open sharing of data sets and predictive modeling and simulation tools. UCSF will provide expertise from a long history of innovation in drug discovery and medicine to improve the lives of patients.

“We at UCSF are eager to lend our expertise to this effort,” said UCSF Chancellor Sam Hawgood, MBBS. “UCSF scientists and clinicians have long been leaders in drug discovery, therapeutics, and cancer biology with the UCSF Helen Diller Family Comprehensive Care Center among the top-ranked cancer institutes in the country. Our role with ATOM is therefore in lock step with UCSF’s mission of advancing health worldwide.”

ATOM welcomes additional public and private partners who share the vision of the consortium, which will have physical headquarters in the Mission Bay neighborhood of San Francisco, adjacent to UCSF’s newest campus.


Tagged with:

About author

Related Articles